Literature DB >> 22241914

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.

David Groheux1, Elif Hindié, Sylvie Giacchetti, Marc Delord, Anne-Sophie Hamy, Anne de Roquancourt, Laetitia Vercellino, Nathalie Berenger, Michel Marty, Marc Espié.   

Abstract

UNLABELLED: Triple-negative breast cancer, an aggressive subtype, represents 15% of invasive breast tumors. This prospective study investigated whether early changes in (18)F-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes.
METHODS: Twenty (M0) patients underwent (18)F-FDG PET/CT at baseline and after the second cycle. NAC was continued irrespective of PET results.
RESULTS: At surgery, 6 patients had a pathologic complete response, whereas 14 had residual tumor. Four patients showed early relapse (in the 2 y after surgery). There were 11 metabolic responders and 9 nonresponders using a 42% decrease in maximum standardized uptake value as a cutoff. In nonresponding patients, the risk of residual tumor at surgery was 100% (vs. 45% in responders; P = 0.014), and the risk of early relapse was 44% (vs. 0%; P = 0.024).
CONCLUSION: A less than 42% decrease in (18)F-FDG uptake at 2 cycles means residual tumor at the end of NAC and a high risk of early relapse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241914     DOI: 10.2967/jnumed.111.094045

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

Review 1.  Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data.

Authors:  Amar U Kishan; Susan A McCloskey
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

2.  Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-14       Impact factor: 9.236

3.  Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.

Authors:  Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Wonshik Han; In Ae Park; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 4.  The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.

Authors:  Fangfang Tian; Guohua Shen; Yunfu Deng; Wei Diao; Zhiyun Jia
Journal:  Eur Radiol       Date:  2017-05-05       Impact factor: 5.315

Review 5.  Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Authors:  Olivier Humbert; Alexandre Cochet; Bruno Coudert; Alina Berriolo-Riedinger; Salim Kanoun; François Brunotte; Pierre Fumoleau
Journal:  Oncologist       Date:  2015-01-05

Review 6.  ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.

Authors:  David Groheux; David Mankoff; Marc Espié; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-13       Impact factor: 9.236

7.  Impact of Using Uniform Attenuation Coefficients for Heterogeneously Dense Breasts in a Dedicated Breast PET/X-ray Scanner.

Authors:  Lawrence R MacDonald; Joseph Y Lo; Gregory M Sturgeon; Chengeng Zeng; Robert L Harrison; Paul E Kinahan; William Paul Segars
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2020-04-29

8.  Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.

Authors:  D Groheux; S Giacchetti; M Delord; A de Roquancourt; P Merlet; A S Hamy; M Espié; E Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-29       Impact factor: 9.236

9.  Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Authors:  Narendra Hulikal; Sivanath Reddy Gajjala; Teck Chand Kalawat; Radhika Kottu; Lakshmi Amancharla Yadagiri
Journal:  Indian J Surg Oncol       Date:  2015-07-22

10.  Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Authors:  Marjan S Bolouri; Sjoerd G Elias; Dorota J Wisner; Spencer C Behr; Randall A Hawkins; Sachiko A Suzuki; Krysta S Banfield; Bonnie N Joe; Nola M Hylton
Journal:  Radiology       Date:  2013-07-22       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.